ADVERTISEMENT

Sun Pharma Q4 Results Review - Stepping Up Specialty Investments In FY25: Prabhudas Lilladher

Guided for high single digit revenue growth and 8-10% R&D spend in FY25.

<div class="paragraphs"><p>Close up tablets arranged for photograph. (Source: pxhere)</p></div>
Close up tablets arranged for photograph. (Source: pxhere)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit